2型糖尿病患者的肝脏监测:重要但不可行?
文章讨论2型糖尿病中代谢功能障碍相关脂肪性肝病(MASLD)的筛查。高达60-70%的2型糖尿病患者有MASLD,纤维化为死亡风险最佳预测指标。多个医学会提倡对2型糖尿病者普遍筛查晚期纤维化,采用FIB-4序贯瞬态弹性成像(TE)路径,但该路径预计使约40%患者转诊TE、20%转诊三级医疗,假发现率高达80%,可行性存疑。减重仍是管理基石。
要点
- 高达60-70%的2型糖尿病患者合并MASLD,纤维化是全因及肝相关死亡风险的最佳预测指标。
- 2型糖尿病者肝相关死亡和肝细胞癌风险增加两至三倍,7.7年内1.3%进展为严重肝病。
- 多个医学会提倡普遍筛查晚期纤维化,FIB-4序贯TE路径预计约40%转诊TE、20%转诊三级医疗,假发现率高达80%。
核心结论
- 2型糖尿病中MASLD患病率高且纤维化影响预后,但现有筛查路径因生物标志物特异性不理想而可行性存疑,亟需更有效的肝脏监测策略。
- 减重(生活方式、药物治疗或减重手术)仍是管理基石,对代谢合并症和MASLD均高度有效。
- 新兴证据提示纤维化生物标志物或可用于基于风险的减重干预靶向选择及潜在的治疗反应监测。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 高达60-70%的2型糖尿病患者患有MASLD。
- 2型糖尿病中晚期肝纤维化患病率仍不确定,基于影像学检查报告的估计为10-20%,可能高估真实患病率。
- 2型糖尿病者肝相关死亡和肝细胞癌风险增加两至三倍,7.7年内1.3%进展为严重肝病。
- 由于缺乏可靠的脂肪变性检测方法,MASLD多为影像学偶然发现。
- 拟议筛查路径预计使约40%的2型糖尿病者转诊TE、20%转诊三级医疗,假发现率高达80%。
关键数值与推荐
- MASLD定义为肝脂肪变性且伴一项或多项代谢综合征特征,无过量饮酒或其他已知脂肪变性原因。
- 多个医学会提倡对2型糖尿病者普遍筛查晚期纤维化。
- 拟议筛查路径包括每年计算FIB-4指数,对中高风险者继以瞬态弹性成像(TE)等二次检测。
临床怎么用
- 减重通过生活方式改变、药物治疗或减重手术实现,仍是管理基石,对代谢合并症和MASLD均高度有效。
- 新兴证据提示纤维化生物标志物或可作为基于风险的减重干预靶向选择工具,并可能用于监测治疗反应。
局限性
- 2型糖尿病中晚期肝纤维化患病率仍不确定,基于影像学检查报告的估计为10-20%,可能高估真实患病率。
- 由于缺乏可靠的脂肪变性检测方法,MASLD多为影像学偶然发现。
- 拟议筛查路径因生物标志物特异性不理想,预计使约40%的2型糖尿病者转诊TE、20%转诊三级医疗,假发现率高达80%,可行性存疑。
- 亟需开发更有效的2型糖尿病肝脏监测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fatty liver plays a pivotal role in the pathogenesis of the metabolic syndrome and type 2 diabetes. According to an updated classification, any individual with liver steatosis and one or more features of the metabolic syndrome, without excess alcohol consumption or other known causes of steatosis, has metabolic dysfunction-associated steatotic liver disease (MASLD). Up to 60-70% of all individuals with type 2 diabetes have MASLD. However, the prevalence of advanced liver fibrosis in type 2 diabetes remains uncertain, with reported estimates of 10-20% relying on imaging tests and likely overestimating the true prevalence. All stages of MASLD impact prognosis but fibrosis is the best predictor of all-cause and liver-related mortality risk. People with type 2 diabetes face a two- to threefold increase in the risk of liver-related death and hepatocellular carcinoma, with 1.3% progressing to severe liver disease over 7.7 years. Because reliable methods for detecting steatosis are lacking, MASLD mostly remains an incidental finding on imaging. Regardless, several medical societies advocate for universal screening of individuals with type 2 diabetes for advanced fibrosis. Proposed screening pathways involve annual calculation of the Fibrosis-4 (FIB-4) index, followed by a secondary test such as transient elastography (TE) for intermediate-to-high-risk individuals. However, owing to unsatisfactory biomarker specificity, these pathways are expected to channel approximately 40% of all individuals with type 2 diabetes to TE and 20% to tertiary care, with a false discovery rate of up to 80%, raising concerns about feasibility. There is thus an urgent need to develop more effective strategies for surveying the liver in type 2 diabetes. Nonetheless, weight loss through lifestyle changes, pharmacotherapy or bariatric surgery remains the cornerstone of management, proving highly effective not only for metabolic comorbidities but also for MASLD. Emerging evidence suggests that fibrosis biomarkers may serve as tools for risk-based targeting of weight-loss interventions and potentially for monitoring response to therapy.
引用
- Qadri S, Yki-Järvinen H. Surveillance of the liver in type 2 diabetes: important but unfeasible? Diabetologia. 2024. PMID: 38334817. doi:10.1007/s00125-024-06087-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。